RxDoctor Payments Data

Michael Bratsch, DO

Family Medicine · Dallas, TXNPI 1811927841

Payments from drug & device makers

$17,453in general payments, 2019–2025

Across 817 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • GSK$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • plus $9K from 48 others

What the payments were for

  • Consulting fees$1,2007%
  • Travel & lodging$3042%
  • Food & beverage$15,86291%
  • Education$870%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,453 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$84,795
Medicare patients
229
Services billed
1,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide196$227,161
EliquisApixaban82$89,180
XareltoRivaroxaban56$53,067
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$51,263
JardianceEmpagliflozin44$36,737
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen824$32,242
JanuviaSitagliptin Phosphate16$26,812
MyrbetriqMirabegron27$22,382
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine12$9,031
SymbicortBudesonide/Formoterol Fumarate21$6,882
Atorvastatin Calcium566$5,934
LantusInsulin Glargine,hum.Rec.Anlog15$5,235
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$4,969
Omeprazole265$4,743
Gabapentin230$4,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,585$227,161196 claims
PfizerEliquis$1,221$89,18082 claims
Johnson & JohnsonXarelto$835$53,06756 claims
GSKTrelegy Ellipta$1,276$51,26360 claims
Boehringer IngelheimJardiance$982$36,73744 claims
MerckJanuvia$302$26,81216 claims
Astellas Pharma US IncMyrbetriq$492$22,38227 claims
AstraZenecaSymbicort$1,437$6,88221 claims
Sanofi-aventis U.S. LLCLantus$121$5,23515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →